WuXi Biologics is launching a $1.4 billion project to build a biologic drug R&D and production center in Singapore. The project will add 120,000 L of capacity to the company’s biomanufacturing network by 2026 and is expected to create 1,500 jobs. Meanwhile, Samsung Biologics will pay $350 million for land in Incheon, South Korea, on which it plans to build a second biologic drug production campus. The site is 30% larger than the firm’s current campus in Songdo, South Korea, where it operates three plants and is building a fourth. Samsung expects the project to generate 4,000 jobs by 2032.